Avastin Can Be Used Off Label For AMD, Says UK MHRA

The UK regulator has clarified its guidance on the use of the anticancer Avastin for age-related macular degeneration, saying that reformulating the drug into small vials for ophthalmic injection represents an off-label use of the Roche product and does not create an unlicensed medicine.

Human eye
The MHRA has changed its guidance on the use of Avastin in the eye

The UK regulatory agency, the MHRA, has changed its advice on the use of Roche’s Avastin (bevacizumab) in the unapproved indication of age-related macular degeneration (AMD) at the request of the High Court, which last year rejected attempts by Novartis and Bayer to stop Avastin being used for the degenerative eye condition in the UK.

The agency now says that if a health professional prescribes or uses Avastin for AMD after it has been compounded...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe